Early switch to oral antibiotics,
does it really help with Noninferior 90-day outcomes in low-risk Staphylococcus aureus bacteraemia?
research showsGrade B. The 90-day composite occurred in 14/108 (13%) versus 13/105 (12%), difference 0.7 points (95% CI -7.8 to 9.1), below the 10-point margin.
ads claimThis is about timing of IV-to-oral transition, not the separate question of which antimicrobial to use.
Useful facts when choosing a product
- Deutsche Forschungsgemeinschaft (DFG) funding was reported.
- Eligibility selected a low-risk subgroup.
What the research actually shows
The primary endpoint was 'any complication related to S aureus bloodstream infection (relapsing S aureus bloodstream infection, deep-seated infection, and mortality attributable to infection) within 90 days.' ① Defect: noninferiority design. ② It matches the listed noninferiority item. ③ The prespecified 10-point margin required the CI upper bound below 10; it was 9.1. ④ A margin naturally addresses an early-switch strategy, but a stricter margin or superiority design was feasible, so it was counted. Outcome assessors were masked. Early closure reflected poor recruitment, not an interim-boundary stop, and was not counted separately.
Why this is classified as B (76)
A 213-person publicly funded hard-outcome RCT met its margin, but single noninferiority evidence gives B, 76.
Counterpoint. Under-recruitment left the upper confidence limit close to the margin.
Rejudgment record. Source checked — Masked assessment of a 90-day clinical composite meeting a 10-point noninferiority margin
| Endpoint | H | Hard endpoint - actual events such as death |
| Replication | R1 | Single confirmatory trial |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E+ | Meets the clinically important threshold |
The scoring table and the verdict agree (B).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Noninferior 90-day composite outcome | B | The 10-point margin was met. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| SABATO 2024 | International randomized open-label noninferiority trial with masked outcome assessors | 105 | Deutsche Forschungsgemeinschaft (DFG) | Composite of SAB-related complications within 90 days | 14/108 (13%) vs 13/105 (12%); difference 0.7 points (95% CI -7.8 to 9.1) | Pivotal evidence |
Receipt — 1 References
All 1 cited sources were verified for existence at the original page (as of 2026-08-26).
Final verification and publication gate: Codex · Verification cutoff: 2026-08-26 · Corrections: none
Cite this verdict
[Chamgap] Benefit of Early Oral Antibiotic Switch for Noninferior 90-Day Outcomes in Low-Risk Staphylococcus aureus Bacteraemia — Evidence Grade B·76. 1 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/early-oral-switch-low-risk-staphylococcus-aureus-bacteraemia-90-day-outcomes/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.